Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ZBTB48 is a priming factor regulating B-cell-specific CIITA expression.
Rane G, Kuan VLS, Wang S, Mok MMH, Khanchandani V, Hansen J, Norvaisaite I, Zulkaflee N, Yong WK, Jahn A, Mukundan VT, Shi Y, Osato M, Li F, Kappei D. Rane G, et al. Among authors: mok mmh. EMBO J. 2024 Dec;43(24):6236-6263. doi: 10.1038/s44318-024-00306-y. Epub 2024 Nov 19. EMBO J. 2024. PMID: 39562739 Free PMC article.
Activation of NOTCH signaling impedes cell proliferation and survival in acute megakaryoblastic leukemia.
Ong KOK, Mok MMH, Niibori-Nambu A, Du L, Yanagida M, Wang CQ, Bahirvani AG, Chin DWL, Koh CP, Ng KP, Yamashita N, Jacob B, Yokomizo T, Takizawa H, Matsumura T, Suda T, Lau JA, Tan TZ, Mori S, Yang H, Iwasaki M, Minami T, Asou N, Sun QY, Ding LW, Koeffler HP, Tenen DG, Shimizu R, Yamamoto M, Ito Y, Kham SKY, Yeoh AE, Chng WJ, Osato M. Ong KOK, et al. Among authors: mok mmh. Exp Hematol. 2024 Sep;137:104255. doi: 10.1016/j.exphem.2024.104255. Epub 2024 Jun 13. Exp Hematol. 2024. PMID: 38876252
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
80 results